The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
How Much Larger Will The Next Generation Drug Conjugates Market Become By 2030 Compared To 2026?
The next generation drug conjugates market has seen swift growth in recent years. This market is set to expand from $2.47 billion in 2025 to $2.85 billion in 2026, achieving a compound annual growth rate (CAGR) of 15.5%. Historically, this expansion can be attributed to the shortcomings of traditional chemotherapy, breakthroughs in biologics research, a rise in cancer cases, the proliferation of specialty pharmaceutical firms, and the successful clinical application of early drug conjugates.
The next generation drug conjugates market is anticipated to experience significant expansion over the coming years. This market is projected to attain a value of $5.1 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 15.7%. The expected growth throughout the forecast period stems from the increasing scope of personalized medicine, the expanding pipelines of oncology drugs, advancements in linker and payload chemistry, greater investments in research and development, and a rise in regulatory approvals. Dominant trends during this period are expected to include the growing adoption of targeted drug delivery systems, an intensified focus on precision oncology therapies, the proliferation of advanced payload technologies, the expanding clinical application of conjugated therapeutics, and a heightened demand for drugs that offer improved safety and high efficacy.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19124&type=smp
What Are The Main Drivers Accelerating The Growth Of The Next Generation Drug Conjugates Market?
The increasing occurrence of cancer is projected to propel the next-generation drug conjugates market going forward. Cancer is characterized by the unregulated growth and spread of abnormal cells within the body. The rise in cancer incidence stems primarily from factors such as an aging population, lifestyle choices, environmental exposures, improved detection methods, genetic predispositions, and infectious agents. Next-generation drug conjugates assist in combating cancer by directly delivering targeted treatments to cancer cells, thereby improving treatment effectiveness while minimizing harm to healthy tissues. For example, in February 2025, Cancer Australia, an Australia-based government agency, reported 4,641 new pancreatic cancer cases in 2024, with 2,414 affecting males and 2,227 affecting females, marking an increase from 3,968 cases recorded in 2023. Therefore, the growing prevalence of cancer is fueling the expansion of the next-generation drug conjugates market.
What Segment Types Are Included In The Next Generation Drug Conjugates Market Analysis?
The next generation drug conjugates market covered in this report is segmented –
1) By Next-Generation Drug Conjugates Type: Peptide Receptor Radionuclide Therapy, Ligand Mediated RNAI Conjugate, Ligand Conjugated Anti Sense Medicine, Peptide Drug Conjugate
2) By Targeting Ligand Type: Amino Sugar, Lipid, Peptide, Small Molecule, Virus-Like Particles
3) By Payload Type: Oligonucleotide, Radionuclide, Peptide, Small Molecule
4) By Therapy: Monotherapy, Combination Therapy
5) By Indication: Gastroenteropancreatic Neuroendocrine Tumors, Prostate Cancer, Leptomeningeal Carcinomatosis Caused By Breast Cancer Brain Metastases, Hereditary Transthyretin Amyloidosis, Atherosclerotic Cardiovascular Diseases, Severe Hypertriglyceridemia, Hereditary Angioedema, Acute Hepatic Porphyria, Other Indications
Subsegments:
1) By Peptide Receptor Radionuclide Therapy (PRRT): Somatostatin Analogues, Radiolabeled Peptides
2) By Ligand Mediated RNAi Conjugate: SiRNA Ligand Conjugates, ShRNA Ligand Conjugates
3) By Ligand Conjugated Anti-Sense Medicine: Oligonucleotide Ligand Conjugates, Antisense Oligonucleotide Ligand Conjugates
4) By Peptide Drug Conjugate: Cytotoxic Peptide Conjugates, Therapeutic Peptide Conjugates
Which Trends Are Guiding The Development Of The Next Generation Drug Conjugates Market?
Leading companies in the next-generation drug conjugates market are increasingly adopting strategic partnerships to bolster their research and development capabilities, accelerate the introduction of innovative products, and expand their market presence. These alliances represent a collaborative process where organizations leverage each other’s core competencies and resources to achieve mutual benefits and success. For example, in November 2023, Prelude Therapeutics Incorporated, a US-based clinical-stage precision oncology company, formed a partnership with AbCellera Biologics Inc., a Canada-based biotechnology company, aimed at developing groundbreaking precision antibody-drug conjugates (ADCs) for oncology. This collaboration will concentrate on the discovery, development, and commercialization of advanced antibody-drug conjugates (ADCs), beginning with a program targeting a SMARCA degrader linked to a novel antibody. The strategic intent is to broaden the therapeutic applications of Prelude’s small-molecule SMARCA2 selective degraders, making them accessible to a wider patient demographic, particularly those with cancers independent of SMARCA4 mutations.
Which Industry Players Are Present In The Next Generation Drug Conjugates Market?
Major companies operating in the next generation drug conjugates market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Novartis International AG, AstraZeneca PLC, Daiichi Sankyo Company Limited, Eisai Co Ltd., Bicycle Therapeutics plc, Zymeworks Inc., Genentech Inc., MacroGenics Inc., Abzena plc, Innate Pharma S.A., CytomX Therapeutics Inc., ImmunoGen Inc., Ascentage Pharma Group International, Mersana Therapeutics Inc., Antengene Corporation Limited, Nurix Therapeutics Inc., Tubulis GmbH
Access The Complete Next Generation Drug Conjugates Market Report:
Which Region Commands The Largest Share Of The Next Generation Drug Conjugates Market?
North America was the largest region in the next generation drug conjugates market in 2025. The regions covered in the next generation drug conjugates market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Next Generation Drug Conjugates Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/sample.aspx?id=19124&type=smp
Browse Through More Reports Similar to the Global Next Generation Drug Conjugates Market 2026, By The Business Research Company
Antibody Drug Conjugates Market Report 2026
https://www.thebusinessresearchcompany.com/report/antibody-drug-conjugates-global-market-report
Conjugate Vaccine Market Report 2026
https://www.thebusinessresearchcompany.com/report/conjugate-vaccine-global-market-report
Bladder Cancer Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/bladder-cancer-drugs-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model